Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study

Overview of attention for article published in Frontiers in endocrinology, March 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 9,221 followers.

Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study https://t.co/9KYC5kvkXy #LongCovid #pwLC

RT @FrontEndocrinol: New Research: Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study: Maturity-onset diabetes…

RT @FrontEndocrinol: New Research: Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study: Maturity-onset diabetes…

RT @FrontEndocrinol: New Research: Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study: Maturity-onset diabetes…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.